Search results for "Estrogen."

showing 10 items of 529 documents

Effects of soy isoflavones on endothelial function in healthy postmenopausal women.

2005

Objective: To evaluate the effects of soy isoflavone administration on endothelial function in healthy postmenopausal women. Design: Sixty naturally postmenopausal women were randomly assigned to receive isoflavone or placebo tablets for 6 months. Endothelium-dependent vasodilatation was measured by brachial reactivity technique along with levels of plasma soluble intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, P-selectin and soluble thrombomodulin, von Willebrand factor, and tissue plasminogen activator. Differences between endothelium-dependent and endothelium-independent vasodilatation were assessed by evaluating brachial reactivity par…

medicine.medical_specialtyAdhesion moleculeEndotheliumBrachial ArteryGenisteinVascular Cell Adhesion Molecule-1PhytoestrogensFibrinogenAdhesion molecule; Endothelial function; Postmenopausal womenchemistry.chemical_compoundVon Willebrand factorInternal medicineMedicineHumansProspective StudiesReactive hyperemiabiologybusiness.industryObstetrics and GynecologyEndothelial functionIsoflavonesMiddle AgedIntercellular Adhesion Molecule-1Postmenopausal womenIsoflavoneGenisteinIsoflavonesDietPostmenopauseVasodilationProspective StudieP-SelectinEndocrinologymedicine.anatomical_structurechemistryPhytoestrogencardiovascular systembiology.proteinFemaleEndothelium VascularSoybeansSoybeanbusinessE-SelectinPlasminogen activatorHumanLipoproteinmedicine.drugMenopause (New York, N.Y.)
researchProduct

OGT and OGA expression in postmenopausal skeletal muscle associates with hormone replacement therapy and muscle cross-sectional area

2013

Protein glycosylation via O-linked N-acetylglucosaminylation (O-GlcNAcylation) is an important post-translational regulatory mechanism mediated by O-GlcNAc transferase (OGT) and responsive to nutrients and stress. OGT attaches an O-GlcNAc moiety to proteins, while O-GlcNAcase (OGA) catalyzes O-GlcNAc removal. In skeletal muscle of experimental animals, prolonged increase in O-GlcNAcylation associates with age and muscle atrophy. Here we examined the effects of hormone replacement therapy (HRT) and power training (PT) on muscle OGT and OGA gene expression in postmenopausal women generally prone to age-related muscle weakness. In addition, the associations of OGT and OGA gene expressions with…

medicine.medical_specialtyAgingGlycosylationTime Factorsmedicine.drug_classPlyometric ExerciseBiologyta3111N-AcetylglucosaminyltransferasesBiochemistryGene Expression Regulation EnzymologicEndocrinologyDownregulation and upregulationInternal medicineGene expressionGeneticsmedicineHumansMuscle StrengthRNA Messengerta315Muscle SkeletalMolecular BiologyFinlandGlyceraldehyde 3-phosphate dehydrogenasePlyometric power trainingEstrogen Replacement Therapyta1182Age FactorsMuscle weaknessSkeletal muscleta3141Cell BiologyMiddle Agedbeta-N-AcetylhexosaminidasesMuscle atrophyPostmenopausePhenotypeTreatment OutcomeEndocrinologymedicine.anatomical_structureEstrogenbiology.proteinFemaleMuscle atrophymedicine.symptomProtein Processing Post-TranslationalMuscle ContractionMuscle contraction
researchProduct

Estradiol or genistein prevent Alzheimer's disease-associated inflammation correlating with an increase PPAR gamma expression in cultured astrocytes.

2009

Inflammation has been implicated in neurodegenerative disorders such as Alzheimer's disease (AD). The main inflammatory players in AD are the glial cells which initiate the inflammatory response. One of the earliest neuropathological changes in AD is the accumulation of astrocytes at sites of A beta deposition. It is desirable to find methods of tipping the balance towards anti-inflammatory state. Estrogenic compounds have shown anti-inflammatory and also antioxidant activity. Astrocytes were pretreated with 17-beta estradiol or with genistein, and 48 h later treated with 5 microM amyloid beta (A beta) for 24 h. We found that A beta induces inflammatory mediators, such as cyclooxygenase 2 (…

medicine.medical_specialtyAmyloid betaInterleukin-1betaGenisteinPeroxisome proliferator-activated receptorNitric Oxide Synthase Type IIInflammationEnzyme-Linked Immunosorbent Assaychemistry.chemical_compoundInternal medicinemedicineAnimalsDrug InteractionsMolecular BiologyProtein Kinase InhibitorsCells Culturedchemistry.chemical_classificationCerebral CortexAmyloid beta-PeptidesbiologyDose-Response Relationship DrugEstradiolTumor Necrosis Factor-alphaGeneral NeuroscienceInterleukinEstrogensGenisteinPeptide FragmentsRatsPPAR gammaEndocrinologymedicine.anatomical_structurechemistryGene Expression RegulationCyclooxygenase 2Astrocytesbiology.proteinNeurogliaTumor necrosis factor alphaNeurology (clinical)medicine.symptomDevelopmental BiologyAstrocyteBrain research
researchProduct

Steroid Receptor Expression in Endometria from Women Treated with Tamoxifen

1998

Abstract Breast cancer patients receiving tamoxifen (Tam) are at an increased risk for developing endometrial carcinomas, possibly due to the partial estrogenic effect of Tam on endometrial cells. Progestational therapy has not routinely been included in Tam regimens. It was our aim to determine the presence of estrogen receptors (ERs) and progesterone receptors (PRs) in normal and abnormal endometria from postmenopausal women with breast cancer who were treated with Tam. Standard immunohistochemical staining of ERs and PRs was performed on paraffin sections from formalin-fixed uterine curettings or hysterectomy specimens from 40 patients who had received 20–40 mg of Tam daily for a minimum…

medicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classReceptor expressionEstrogen receptorBreast NeoplasmsEndometriumEndometriumBreast cancerInternal medicineEndometrial PolypHumansMedicineRetrospective Studiesbusiness.industryObstetrics and Gynecologymedicine.diseasePostmenopauseTamoxifenmedicine.anatomical_structureEndocrinologyReceptors EstrogenOncologyEstrogenAdenocarcinomaFemaleReceptors ProgesteronebusinessTamoxifenmedicine.drugGynecologic Oncology
researchProduct

Endometrial response to concurrent treatment with vaginal progesterone and transdermal estradiol.

2012

ABSTRACT Objective To describe the effect of the intermittent administration of vaginal progesterone and a low-dose estradiol patch on endometrial stability, as assessed by the rate of amenorrhea and endometrial stimulation. Methods This was an open study in which 64 moderately symptomatic, postmenopausal women were treated in the outpatient clinic of our University Hospital for different intervals up to 1 year. The treatment consisted of a combination of patches delivering 25 µg/day estradiol and intravaginal pills containing 100 mg of micronized progesterone. Patches and pills were administered concomitantly in a twice-a-week protocol. The endometrial response was assessed by endovaginal …

medicine.medical_specialtyBiopsyEndometriumAdministration CutaneousEndometriumBiopsymedicineOutpatient clinicHumansProgesteroneTransdermalUltrasonographyGynecologymedicine.diagnostic_testEstradiolUterine Hemorrhagebusiness.industryEstrogen Replacement TherapyObstetrics and GynecologyGeneral MedicineMiddle AgedUniversity hospitalPostmenopauseAdministration Intravaginalmedicine.anatomical_structurePillAmenorrheaFemaleUterine Hemorrhagemedicine.symptomAtrophybusinessClimacteric : the journal of the International Menopause Society
researchProduct

Steroid activities comparison of natural and food wrap compounds in human breast cancer cell lines

2004

Abstract In this study, we tested and compared the endocrine disruption activities of compounds in materials used to package foods (bisphenol A, bisphenol F, and bisphenol A diglycidylether BADGE) with natural molecules (genistein, apigenin, kaempferol, and tangeretin) in the human breast cancer cell lines MCF-7 (ER + ) and MDA-MB453 (AR + ; GR + ). Octylphenol was also chosen as a xenoestrogen reference. Two compounds had no estrogenic activity: BADGE and tangeretin. Genistein was the most active compound in the E-Screen assay with MCF-7, followed by octylphenol, bisphenol F, bisphenol A and apigenin, with kaempferol the least potent. All estrogenic compounds competed with 17β-estradiol fo…

medicine.medical_specialtyBisphenol A[SDV]Life Sciences [q-bio]medicine.medical_treatmentGenisteinAntineoplastic AgentsBreast NeoplasmsEndocrine SystemToxicologySteroid03 medical and health scienceschemistry.chemical_compoundTangeretin0302 clinical medicinePhenolsInternal medicineTumor Cells CulturedmedicineAnticarcinogenic AgentsHumansEstrogens Non-SteroidalApigeninBenzhydryl CompoundsKaempferolsComputingMilieux_MISCELLANEOUS030304 developmental biologyFlavonoids0303 health sciencesDose-Response Relationship DrugFood PackagingGeneral MedicineFlavonesGenistein3. Good health[SDV] Life Sciences [q-bio]XenoestrogenEndocrinologyReceptors EstrogenchemistryMCF-7Receptors Androgen030220 oncology & carcinogenesisApigeninCarcinogensEpoxy CompoundsFemaleKaempferolhormones hormone substitutes and hormone antagonistsFood Science
researchProduct

Impact of estrogens on atherosclerosis and bone in the apolipoprotein E-deficient mouse model.

2014

Objective The common inflammatory pathophysiology has nourished the hypothesis of a relationship between osteoporosis and cardiovascular disease. Estrogens are key agents in the modulation of both processes. We investigated whether induction of atherosclerosis affects bone and whether estrogens modulate both processes. Methods Female apolipoprotein E-deficient mice (a well-established model of atherogenesis) were ovariectomized or falsely operated and fed either standard diet or high-fat diet (HFD). Six animals were included in each of the four groups. To clarify mechanisms, we treated preosteoblastic MC3T3-E1 cells with mouse serum. Results Physiological levels of estrogens in falsely oper…

medicine.medical_specialtyBone densityApolipoprotein BOvariectomyOsteoporosisDiet High-FatBone resorptionMiceApolipoproteins EBone DensityTrabecular PatternInternal medicinemedicineAnimalsHumansBone ResorptionBone mineralbiologybusiness.industryObstetrics and GynecologyEstrogensmedicine.diseaseAtherosclerosisDisease Models AnimalEndocrinologymedicine.anatomical_structureOvariectomized ratbiology.proteinOsteoporosisCortical boneFemalebusinessMenopause (New York, N.Y.)
researchProduct

Expression of Wild-Type and Variant Estrogen Receptor Alpha in Liver Carcinogenesis and Tumor Progression.

2011

Although estrogen receptors (ERs) are expressed in human hepatocellular carcinoma (HCC), several clinical trials have failed to demonstrate the efficacy of antiestrogen treatment in HCC patients. Recently, the identification of several ER splicing variants has enlightened the complex nature of estrogen signaling in peripheral tissues; this may help understanding estrogen role in either nontumoral or malignant nonclassical target organs, including liver. In this work we have investigated mRNA expression of wild-type and splice variants of ERα in nontumoral, cirrhotic, and malignant human liver, as well as in HCC cell lines, using an exon-specific reverse transcription polymerase chain reacti…

medicine.medical_specialtyCarcinoma Hepatocellularmedicine.drug_classEstrogen receptorBiologyBiochemistryAromataseCell Line TumorInternal medicineGene OrderGeneticsmedicineHumansRNA MessengerneoplasmsMolecular BiologyLiver NeoplasmsEstrogen Receptor alphaWild typeExonsHep G2 Cellsmedicine.diseaseAntiestrogenGene Expression Regulation NeoplasticReverse transcription polymerase chain reactionAlternative SplicingCell Transformation NeoplasticEndocrinologyLiverEstrogenTumor progressionHepatocellular carcinomaCancer researchMolecular MedicineEstrogen receptor alphaLiver carcinogenesis Estrogen receptors tumor progressionBiotechnology
researchProduct

Aging and systemic hormonal status affects the circulating miR-21, miR-146a and FasL levels

2015

MicroRNAs are small molecules, found in all cell types and body fluids, which most commonly affect negatively to gene expressions by translational repression. Their role in various physiological conditions and diseases has been emphasized during the last twenty years. In our recent studies with postmenopausal monozygotic twin sisters (n=11), we have investigated how different systemic hormonal status affects the levels of specific circulating microRNAs and other molecules related to inflammation and apoptosis, both processes associated with aging. Our results have shown that the systemic levels of miR-21, miR-146a and Fas ligand are lower within the postmenopausal women who are using estrog…

medicine.medical_specialtyCell typemedicine.drug_classMonozygotic twinInflammationBiologyFas ligandInternal medicinemicroRNAmedicinehormonesta1184ta1182ta3141General MedicinemiR-146hormonitFasLCirculating MicroRNAEndocrinologyEstrogenagingsmiR-21medicine.symptomHormoneRNA and Disease
researchProduct

Behandlung der ausgeprägten Pubertätsgynäkomastie mit Tamoxifen

1987

Based on the good results of another author 10 boys with marked pubertal gynecomastia were treated with the antioestrogen Tamoxifen (Nolvadex) at a dose of 20-40 mg/d orally for 2-12 months. In most cases the gynecomastia decreased totally, only two patients experienced palpable subareolar glandular tissue at the end of therapy. Side effects were not noted. During therapy levels of estradiol and testosteron increased, with a more pronounced elevation of estradiol. Basal values of LH and FSH remained nearly unchanged, but LH showed an increased response to LH-RH, which could be explained by the antioestrogenic effect of Tamoxifen at the hypothalamic level. The reduction of breast size in spi…

medicine.medical_specialtyChemotherapyEnd of therapybusiness.industrymedicine.medical_treatmentTherapeutic effectEstrogen receptormedicine.diseaseBlockadeBasal (phylogenetics)EndocrinologyGynecomastiaInternal medicinePediatrics Perinatology and Child Healthmedicineskin and connective tissue diseasesbusinesshormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drugKlinische Pädiatrie
researchProduct